At Ingenes, innovation and science are not just part of our daily practice—they position us at the forefront of reproductive medicine worldwide. Today, we proudly share news that reaffirms this commitment: our scientific article on the combined use of Ovagen and Endogen has been cited in two high-impact journals from prestigious scientific publishers: Cell Press and Springer Nature.
This recognition not only validates the effectiveness of our personalized fertility solutions but also highlights Ingenes as a benchmark in the development of regenerative therapies in assisted reproduction.
What is our article about?
The article, titled “Personalized regenerative strategies and molecular diagnosis for in vitro fertilization success: a case report” (DOI: 10.1016/j.heliyon.2024.e39584), presents the first documented clinical success case that combined two of our most innovative regenerative solutions: Ovagen, focused on ovarian restoration, and Endogen, an advanced cell therapy for regenerating the endometrium.
This study was conducted by our clinical and medical research team and represents a significant step forward in personalized medicine applied to fertility. Its publication has generated interest in the international scientific community and has been cited in new research on recurrent pregnancy loss, implantation failure, and regenerative strategies in assisted reproduction.
Where has the study been cited?
To date, the article has been cited in:
- Motlagh Asghari, K., et al. (2024). Revolutionized attitude toward recurrent pregnancy loss and recurrent implantation failure based on precision regenerative medicine. Published in Heliyon, Volume 10, by Cell Press.
Reference 159 – Read full article here - Karadbhajne, P., et al. (2024). Enhancing Endometrial Health in Assisted Reproductive Technology (ART): Evaluating Autologous Endometrial Cells and Platelets-Rich Plasma (PRP) via Hysteroscopic Injections. Published in Cureus, by Springer Nature.
Reference 23 – Read full article here
Both articles emphasize the importance of implementing personalized regenerative strategies to solve some of the most complex fertility challenges, such as recurrent pregnancy loss, low ovarian quality, or chronic endometrial insufficiency. Most importantly, they directly reference the clinical case reported by Ingenes, where a patient achieved a successful pregnancy thanks to the combined use of Ovagen and Endogen.
What is Ovagen?
Ovagen is an innovative ovarian regeneration therapy exclusive to Ingenes, developed for women experiencing declining ovarian quality due to age, low ovarian reserve or response, previous IVF failures, or a diagnosis of ovarian insufficiency.
It is a complementary treatment that uses personalized biological regeneration through biofactors derived from the patient’s own cells. These growth factors stimulate the ovary’s natural mechanisms, improving the cellular environment and promoting more efficient and healthier ovulation.
Ovagen has been especially helpful for:
- Women over the age of 35
- Patients with previously failed IVF cycles
- Cases of poor ovarian response
- Women diagnosed with low ovarian reserve
The treatment is performed on an outpatient basis and is designed to be integrated as a preparatory phase before IVF, improving the ovary’s initial condition and increasing the chances of obtaining viable eggs.
What is Endogen?
Endogen (Stem Cells) is a groundbreaking endometrial regeneration treatment designed to improve uterine receptivity in women with thin endometrium, Asherman’s syndrome, or a history of implantation failure.
Using autologous stem cells (derived from the patient herself) and prepared in the lab, Endogen aims to restore endometrial health by activating regeneration, vascularization, and tissue remodeling processes.
This solution may be recommended when:
- The endometrium does not reach the required thickness for successful implantation
- Signs of chronic inflammation or endometritis are present
- Multiple embryo transfers have failed
- Improved receptivity is needed before IVF or embryo transfer
Endogen is part of a comprehensive protocol tailored to each patient and administered under strict medical supervision and ultrasound monitoring.
Why is this scientific citation so important?
In the scientific world, being cited by other researchers is a key way to validate the impact of your work. It means that other professionals have found value in your findings and are using them as a foundation for new studies, developments, or treatments.
Ingenes being cited in publications by Cell Press and Springer Nature—two of the most respected publishers in biomedical science—is a historic milestone not only for our institution but for reproductive medicine in Latin America.
It demonstrates that knowledge generated in Mexico, based on real patient experiences, is directly influencing the global evolution of reproductive medicine.
One step closer to transforming fertility through science
At Ingenes, we firmly believe that science transforms lives. And with Ovagen® and Endogen, we’ve proven it: beyond offering clinical alternatives to our patients, we’re paving the way for thousands of people around the world who still haven’t found answers in traditional treatments.
The combination of these therapies has improved ovarian and endometrial conditions in cases where conventional IVF had low chances of success. Today, we know that personalized regeneration is not only possible—it is a clinical reality backed by scientific evidence.
What’s next for Ingenes and regenerative medicine?
This recognition is just the beginning. In the coming months, our team will continue sharing results, expanding clinical research, and developing new cases with personalized approaches.
Our goal is clear: to help more people have a baby using their own eggs and their own body, even when facing complex diagnoses. We will continue investing in cutting-edge science, breakthrough technology, and warm, human-centered care.
Conclusion
The publication and international citations of our article on Ovagen and Endogen mark a milestone in Ingenes’ history. They are the result of years of research, teamwork, and—most importantly—the trust of our patients.
We celebrate this achievement with pride, but also with responsibility: to continue offering the most innovative and safest solutions for those who trust us to fulfill their dream of having a baby.
Want to know if Ovagen or Endogen can help in your case? Schedule your consultation with our specialists and discover how regenerative science can transform your fertility.
